Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$335.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yaacov Yanay
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Beta
- 0.69
- Country
- IL
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -30.49
Financials
Revenue
$335.0K-98.9%Net Income
$-5.88MEBITDA
$-5.42MFree Cash Flow
$-4.47MEPS (diluted)
$-0.54Shares Outstanding (diluted)
10.82M+973.8%Operating Expenses
$5.62MCash & Debt
$7.80MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.02M | $-23.82M | $-2.44 |
| 2025 | $1.34M | $-22.58M | $-3.56 |
| 2024 | $326.0K | $-20.89M | $-3.99 |
| 2023 | $287.0K | $-28.32M | $-6.18 |
| 2022 | $234.0K | $-41.24M | $-10.24 |
| 2021 | $0.00 | $-49.87M | $-14.19 |
| 2020 | $23.0K | $-29.15M | $-12.80 |
| 2019 | $54.0K | $-35.31M | $-23.20 |
| 2018 | $50.0K | $-26.13M | $-19.74 |
| 2017 | $0.00 | $-27.81M | $-25.45 |
| 2016 | $2.85M | $-23.25M | $-23.38 |
| 2015 | $379.0K | $-24.68M | $-28.09 |
| 2014 | $379.0K | $-26.93M | $-33.92 |
| 2013 | $679.0K | $-21.16M | $-30.50 |
Valuation
PLURhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
105+5.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·1d ago·Neutral
Ever After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat Productivity HAIFA, Israel and EDINBURGH, Scotland, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Ever After Foods (EAF) and Roslin Technologies today announced results from their joint cultivated meat production program. Combining Roslin Technologies' advanced cell platform with Ever After Foods' proprietary Edible Packed Bed (EPB™) technology, the companies demonstrated substantial gains in protein and biomass productivity whil
View source ↗ - Newsglobenewswire.com·48d ago·Negative
…ffering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor HAIFA, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human Health & Longevity and (ii) FoodTech & Bio-Farming, today announced that it has entered into a securities purchase agreement with a single healthcare fo…
View source ↗ - Newsglobenewswire.com·58d ago·Neutral
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence
View source ↗
Earnings
Thu, Nov 5(in 3 weeks)
Typical surprise +1.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Sep 10$-0.54 vs $-0.66beat
- Thu, May 14$-0.55 vs $-0.66beat
- Thu, Feb 12$-0.71 vs $-0.65miss
- Wed, Nov 12$-0.65 vs $-0.74beat
- Wed, Sep 17$-2.62 vs $-0.65miss
- Tue, May 13$-0.94 vs $-0.73miss
Estimates and results for PLUR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PLUR officers and directors.
- Bought
- $12.0m
- Sold
- $3.8m
20 trades
12 trades
- Manieu Alexandre Weinsteinbought
- Manieu Alexandre Weinsteinbought
- Aberman Zamisold
- Aberman Zamibought
- Clover Wolf Capital - Limited Partnershipsold
- Clover Wolf Capital - Limited Partnershipsold
- Clover Wolf Capital - Limited Partnershipsold
- Clover Wolf Capital - Limited Partnershipsold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PLUR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.